Sandbox: sadaf: Difference between revisions
Jump to navigation
Jump to search
Line 9: | Line 9: | ||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
! colspan="10" |Clinical manifestations | |||
! colspan="10" rowspan="2" |Para−clinical findings | ! colspan="10" rowspan="2" |Para−clinical findings | ||
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
Line 21: | Line 20: | ||
! | ! | ||
! | ! | ||
! colspan=" | ! | ||
! rowspan="4" |Age range | |||
! rowspan="4" |History | |||
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | |||
| | |||
| | |||
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ||
|- | |- | ||
! | ! | ||
Line 30: | Line 33: | ||
! | ! | ||
! | ! | ||
| | |||
| | |||
! colspan="9" |Lab Findings | ! colspan="9" |Lab Findings | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
|- | |- | ||
! | |||
! | ! | ||
! | ! | ||
Line 39: | Line 45: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash | |||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ||
! | ! | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Splenomegaly | ||
! | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Jaundice | ||
! rowspan="2" |Other | |||
! colspan="3" |CBC | ! colspan="3" |CBC | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ||
Line 55: | Line 59: | ||
! | ! | ||
|- | |- | ||
! | !Decreased platelet production | ||
!Platelet destruction in bloodstream | !Platelet destruction in bloodstream | ||
!Platelet destruction in spleen/liver | !Platelet destruction in spleen/liver | ||
! | !Inherited | ||
! | !Acquried | ||
!BP | |||
!Plt | !Plt | ||
!HB | !HB | ||
Line 66: | Line 71: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PTT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |BT | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |UA | ||
|- | |- | ||
! rowspan=" | ! rowspan="15" |Hematology | ||
! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders | ! rowspan="4" align="center" style="background:#DCDCDC;" + |Bone marrow disorders | ||
!Myelodysplastic syndromes | !Myelodysplastic syndromes | ||
! | ! | ||
| + | | + | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 81: | Line 88: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 103: | Line 108: | ||
! | ! | ||
| + | | + | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 111: | Line 118: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 133: | Line 138: | ||
! | ! | ||
| + | | + | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 141: | Line 148: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 163: | Line 168: | ||
! | ! | ||
| + | | + | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 171: | Line 178: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 225: | Line 230: | ||
! | ! | ||
!+ | !+ | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
! | |||
!DIC | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 253: | Line 289: | ||
! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ! rowspan="7" align="center" style="background:#DCDCDC;" + |Congenital platelet disorders | ||
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 263: | Line 301: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 283: | Line 319: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 293: | Line 331: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | | | ||
| | | | ||
Line 313: | Line 349: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 323: | Line 361: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | | | ||
| | | | ||
Line 343: | Line 379: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 353: | Line 391: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 373: | Line 409: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 383: | Line 421: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | | | ||
| | | | ||
Line 403: | Line 439: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Alport syndrome | ! align="center" style="background:#DCDCDC;" + |Alport syndrome | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 413: | Line 451: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | | | ||
| | | | ||
Line 433: | Line 469: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ! align="center" style="background:#DCDCDC;" + |Von Willebrand disease | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 443: | Line 481: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 497: | Line 533: | ||
! | ! | ||
|Antibody-mediated platelet destruction | |Antibody-mediated platelet destruction | ||
| | |||
| + | |||
| | | | ||
| | | | ||
Line 506: | Line 544: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 528: | Line 564: | ||
! | ! | ||
! | ! | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 537: | Line 575: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 622: | Line 658: | ||
! align="center" style="background:#DCDCDC;" + |Sepsis | ! align="center" style="background:#DCDCDC;" + |Sepsis | ||
!Direct bone marrow suppression | !Direct bone marrow suppression | ||
!+ | |||
!+ | !+ | ||
! | |||
! | ! | ||
! | ! | ||
Line 631: | Line 669: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 652: | Line 688: | ||
! align="center" style="background:#DCDCDC;" + |Helicobacter pylori | ! align="center" style="background:#DCDCDC;" + |Helicobacter pylori | ||
!Immune thrombocytopenia | !Immune thrombocytopenia | ||
! | |||
!+ | |||
! | ! | ||
! | ! | ||
Line 661: | Line 699: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 682: | Line 718: | ||
! align="center" style="background:#DCDCDC;" + |Tick-borne infection | ! align="center" style="background:#DCDCDC;" + |Tick-borne infection | ||
| | | | ||
| | |||
| + | |||
| | | | ||
| | | | ||
Line 691: | Line 729: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 746: | Line 782: | ||
!Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | !Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | ||
! | ! | ||
! | !+ | ||
! | ! | ||
! | ! | ||
Line 776: | Line 812: | ||
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites | ! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites | ||
! align="center" style="background:#DCDCDC;" + |Malaria | ! align="center" style="background:#DCDCDC;" + |Malaria | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 786: | Line 824: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 806: | Line 842: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Babesiosis | ! align="center" style="background:#DCDCDC;" + |Babesiosis | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 816: | Line 854: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 849: | Line 885: | ||
* Quinine | * Quinine | ||
|Occurrence of drug-dependent, platelet-reactive antibodies | |Occurrence of drug-dependent, platelet-reactive antibodies | ||
| | |||
| + | |||
| | | | ||
| | | | ||
Line 858: | Line 896: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 880: | Line 916: | ||
! | ! | ||
| | | | ||
| | |||
| + | |||
| | | | ||
| | | | ||
Line 889: | Line 927: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 912: | Line 948: | ||
| | | | ||
| + | | + | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 920: | Line 958: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 943: | Line 979: | ||
|Predictable, dose-dependent myelosuppression | |Predictable, dose-dependent myelosuppression | ||
| + | | + | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 951: | Line 989: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 972: | Line 1,008: | ||
!OTC agents | !OTC agents | ||
!Quinine-containing beverages | !Quinine-containing beverages | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 982: | Line 1,020: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,006: | Line 1,042: | ||
| | | | ||
| + | | + | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 1,014: | Line 1,052: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,035: | Line 1,071: | ||
!Portal hypertension | !Portal hypertension | ||
! | ! | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 1,045: | Line 1,083: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 1,069: | Line 1,105: | ||
!platelet destruction | !platelet destruction | ||
! | ! | ||
! | !+ | ||
! | ! | ||
! | ! | ||
Line 1,100: | Line 1,136: | ||
!platelet destruction | !platelet destruction | ||
! | ! | ||
! | !+ | ||
! | ! | ||
! | ! | ||
Line 1,131: | Line 1,167: | ||
!platelet destruction | !platelet destruction | ||
! | ! | ||
! | !+ | ||
! | ! | ||
! | ! | ||
Line 1,162: | Line 1,198: | ||
! | ! | ||
! | ! | ||
! | !+ | ||
! | ! | ||
! | ! | ||
Line 1,225: | Line 1,261: | ||
! | ! | ||
! | ! | ||
! | !+ | ||
! | ! | ||
! | ! |
Revision as of 21:31, 14 August 2018
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Mechanism | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age range | History | Symptoms | Signs | |||||||||||||||||||||||||||
Lab Findings | Imaging | |||||||||||||||||||||||||||||
Severity | Fever | Rash | Bleeding | Splenomegaly | Jaundice | Other | CBC | PBS | Bone marrow exam | |||||||||||||||||||||
Decreased platelet production | Platelet destruction in bloodstream | Platelet destruction in spleen/liver | Inherited | Acquried | BP | Plt | HB | WBC | PT | PTT | BT | UA | ||||||||||||||||||
Hematology | Bone marrow disorders | Myelodysplastic syndromes | + | |||||||||||||||||||||||||||
Aplastic anemia | + | |||||||||||||||||||||||||||||
Acute leukemia | + | |||||||||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | + | Diagnosis of exclusion | ||||||||||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | + | ||||||||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | + | |||||||||||||||||||||||||||||
DIC | ||||||||||||||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | |||||||||||||||||||||||||||||
Bernard-Soulier syndrome | ||||||||||||||||||||||||||||||
Gray platelet syndrome | ||||||||||||||||||||||||||||||
Wiskott-Aldrich syndrome | ||||||||||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | ||||||||||||||||||||||||||||||
Alport syndrome | ||||||||||||||||||||||||||||||
Von Willebrand disease | ||||||||||||||||||||||||||||||
Nutrient deficiencies | Folate, vitamin B12, copper | an autoimmune mechanism | + | |||||||||||||||||||||||||||
Rheumatologic/autoimmune disorders | Immune thrombocytopenia | Antibody-mediated platelet destruction | + | Moderate to severe | - | |||||||||||||||||||||||||
Systemic lupus erythematosus (SLE) | ||||||||||||||||||||||||||||||
Antiphospholipid syndrome (APS) | autoantibody-mediated syndrome | |||||||||||||||||||||||||||||
Felty's syndrome | splenomegaly | |||||||||||||||||||||||||||||
Infection-induced | Bacterial infections | Sepsis | Direct bone marrow suppression | + | + | |||||||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | + | ||||||||||||||||||||||||||||
Tick-borne infection | + | |||||||||||||||||||||||||||||
Viral infections | HIV |
|
+ | |||||||||||||||||||||||||||
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus | + | |||||||||||||||||||||||||||||
Intracellular parasites | Malaria | |||||||||||||||||||||||||||||
Babesiosis | ||||||||||||||||||||||||||||||
Medication/toxicity | Drug-induced immune thrombocytopenia |
|
Occurrence of drug-dependent, platelet-reactive antibodies | + | ||||||||||||||||||||||||||
Heparin-induced thrombocytopenia | + | |||||||||||||||||||||||||||||
Cytotoxic chemotherapy | + | |||||||||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | + | ||||||||||||||||||||||||||||
OTC agents | Quinine-containing beverages | |||||||||||||||||||||||||||||
GI | Chronic liver disease | + | Mild | |||||||||||||||||||||||||||
Portal hypertension | ||||||||||||||||||||||||||||||
Vascular | Giant capillary hemangioma | platelet destruction | + | |||||||||||||||||||||||||||
Aortic aneurysm | platelet destruction | + | ||||||||||||||||||||||||||||
Cardiopulmonary bypass | platelet destruction | + | ||||||||||||||||||||||||||||
Other | Alcohol | + | ||||||||||||||||||||||||||||
Post-transfusion purpura | immune-mediated platelet destruction | |||||||||||||||||||||||||||||
Gestational thrombocytopenia | + |